Health and wellness firm LifeVantage Q1 revenue misses estimates

Overview

• LifeVantage fiscal Q1 revenue increased 0.7% yr/yr but missed analyst expectations

• Adjusted EPS for fiscal Q1 rose to $0.18 from $0.15 a year ago

• Company highlights strategic acquisition of LoveBiome as a pivotal milestone

Outlook

• Company reiterates FY 2026 revenue guidance of $225 mln to $240 mln

• LifeVantage expects FY 2026 adjusted EPS of $1.00 to $1.15

• Company anticipates higher H2 revenue due to seasonality and LoveBiome acquisition

Result Drivers

• REGIONAL REVENUE - Revenue in the Americas increased 0.8%, while Asia/Pacific & Europe saw a 0.4% increase, with a decline when excluding currency effects

• EXPENSES IMPACT - Increase in commissions and incentives expenses due to changes in sales mix and promotional programs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for LifeVantage Corp is $24.00, about 69.4% above its November 3 closing price of $7.34

• The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release: ID:nGNX1qMsFW

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.